Shares of Curis CRIS decreased after the company reported Q4 results.
Quarterly Results
Earnings per share increased 57.69% year over year to ($0.11), which missed the estimate of ($0.09).
Revenue of $3,024,000 declined by 8.00% year over year, which beat the estimate of $2,840,000.
Guidance
Curis hasn't issued any earnings guidance for the time being.
Curis hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Mar 16, 2021
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1827/40133
Technicals
52-week high: $13.44
Company's 52-week low was at $0.62
Price action over last quarter: Up 778.51%
Company Description
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
